The role of EGFR-targeting strategies in the treatment of head and neck cancer
Didier Dequanter, Mohammad Shahla, Pascal Paulus, Philippe H Lothaire
Department of Surgery, CHU Charleroi (Hopital Andre Vésale), Montigny le Tilleul, Belgium
Abstract: With its targeted mechanism of action and synergistic activity with current treatment modalities, cetuximab is a potentially valuable treatment option for patients with recurrent and/or metastatic squamous cell cancer of the head and neck who have progressed on cisplatin-based chemotherapy. The use of cetuximab in combination with radiotherapy as definitive treatment for locoregionally advanced squamous cell cancer of the head and neck is generally restricted to patients unfit to receive cisplatin-based chemoradiation, which is still considered the standard of care. The effect of this epidermal growth factor receptor antagonist occurs without any change in the pattern and the severity of toxicity usually associated with head and neck radiation.
Keywords: cetuximab, SCCHN, radiotherapy